Enzo's Q4 Revenues Fall, Losses Widen; Company to Recognize $2M From Sigma Settlement in Q1 '07 | GenomeWeb
NEW YORK (GenomeWeb News) - Enzo Biochem on Friday reported an 8.7-percent decline in revenues atop a widened net loss for its fourth fiscal quarter.
 
For the quarter ended July 31, Enzo posted revenues of $9.9 million, down from $10.9 million in the year-ago period.
 
The company’s quarterly net loss more than doubled to $4.5 million from $2 million in the fourth quarter of 2005.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.